Ross Weinreb

Stock Analyst at Goldman Sachs

(n/a)
# 4,528
Out of 4,853 analysts
3
Total ratings
n/a
Success rate
-45.51%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Ross Weinreb

Relmada Therapeutics
Mar 24, 2022
Maintains: Buy
Price Target: $69$53
Current: $0.74
Upside: +7,082.55%